Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
sotyktu
Synonyms :
deucravacitinib
Class :
Dermatologics, tyrosine kinase inhibitors
Brand Name :
sotyktu
Synonyms :
deucravacitinib
Class :
Dermatologics, tyrosine kinase inhibitors
may increase the immunosuppressive effects of corticosteroids
may increase the immunosuppressive effects of corticosteroids
may increase the immunosuppressive effects of corticosteroids
may increase the immunosuppressive effects of corticosteroids
may increase the immunosuppressive effects of corticosteroids
may decrease the therapeutic effect of COVID-19
may increase the immunosuppressive effects of corticosteroids
may decrease the therapeutic effect of influenza virus vaccine
may decrease the therapeutic effect of rabies vaccine
may have an increased immunosuppressive effect when combined with corticosteroids
may have an increased immunosuppressive effect when combined with corticosteroids
may have an increased immunosuppressive effect when combined with corticosteroids
may have an increased immunosuppressive effect when combined with corticosteroids
may have an increased immunosuppressive effect when combined with corticosteroids
may increase the immunosuppressive effects
may increase the immunosuppressive effects
may increase the adverse effects
may increase the immunosuppressive effects
may increase the immunosuppressive effects
may increase the immunosuppressive effects
may increase the immunosuppressive effects
may increase the therapeutic effect of immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
deucravacitinib: they may increase the immunosuppressive effect of immunostimulants
deucravacitinib: they may increase the immunosuppressive effect of immunostimulants
deucravacitinib: they may increase the immunosuppressive effect of immunostimulants
deucravacitinib: they may increase the immunosuppressive effect of immunostimulants
deucravacitinib: they may increase the immunosuppressive effect of immunostimulants
may increase the immunosuppressive effects
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressive agents
may increase the immunosuppressive effect of Immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
Frequency defined:Â Â
>10%Â
Upper respiratory tract infectionsÂ
InfectionsÂ
1-10%Â
Herpes simplexÂ
FolliculitisÂ
Increased levels of blood creatinine phosphokinaseÂ
Mouth ulcersÂ
AcneÂ
<1%Â
Herpes zosterÂ
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: deucravacitinibÂ
Pronounced: (due krav a sye ti nib)Â
Why do we use deucravacitinib?Â
It is used in the treatment of psoriasisÂ
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
